Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,477 total articles
Microchip is showing clear signs of a business recovery driven by a fast-growing data center franchise and product introductions across power, MCU, and analog. The market has only partially re-priced that improvement: free cash flow of $760M and a $42.3B market cap imply the multiple has room to compress as revenues and margins improve. This trade …
Kaspi.kz remains a dominant, closed-loop fintech in Kazakhstan with attractive cash returns and a cheap earnings multiple. Management's Turkey push via Rabobank A.Ş. is the main growth kicker but also the primary source of market skepticism. This trade buys the moat in Kazakhstan while keeping a tight stop to limit losses if international execution…
Netflix is increasingly a two-headed company: streaming subscriptions and a nascent ad business. The market still appears to underweight the long-term revenue and margin optionality from ads. This trade targets a mid-term re-rating tied to improving ad metrics and advertiser momentum.
Century Aluminum (CENX) is trading at $44.86 with a market cap near $4.44B, a P/E of 12.7 and clear domestic expansion catalysts. With recent government-backed tariff incentives, a Mt. Holly capacity increase, and a new smelter partnership in Oklahoma, the company looks set to convert commodity tailwinds into earnings growth. This trade idea outlin…
Ondas (ONDS) has had a parabolic run and faces dilution headlines from an acquisition and share issuance, but the underlying business is accelerating: raised 2026 revenue guidance to $390M+, multi‑hundred‑million backlog, recent multi‑week order wins, and an enterprise value that implies a less-stretched forward multiple. This trade idea outlines a…
Broadcom's stock has moved with every cloud capex headline, but the company's durable advantage is the combination of high-margin infrastructure software and bespoke silicon deals that lock in customers. With free cash flow of $32.8B, ROE above 33%, and an enterprise value near $1.87T, AVGO is richly priced but not without runway. This trade idea t…
Alibaba's Cloud is positioned to capture a disproportionate share of Chinese enterprise AI spend as Beijing clarifies rules and localizes infrastructure. The stock trades at a reasonable multiple (P/E ~18.3, PB ~1.78) for a company with a $275.7B market cap and an entrenched commerce-to-cloud flywheel. This trade idea lays out an actionable long wi…
Oracle shares have been punished on concerns about heavy AI capex, customer concentration and higher leverage. At $119.97 the stock already discounts a lot of downside. Balance-sheet and valuation metrics suggest a tactical long for traders who want exposure to AI infrastructure upside while limiting downside with a clearly defined stop.
SES (SGBAF) is showing signs that long-promised C-band monetization is moving from theory to cash flow. Technicals sit near short-term support while short interest—though still large—has come down in July, suggesting a repositioning that could fuel short-covering rallies. This trade idea lays out an entry at $8.15, a stop at $6.50 and a $11.00 targ…
Nebius is the AI infrastructure 'neocloud' the market has been renting instead of buying. Recent beats in revenue and a big Nvidia stake have driven a parabolic run; today’s retracement offers a disciplined entry for a mid-term swing trade with defined risk and a clear target.
Alta Equipment Group looks like a classic levered recovery story. Q2 showed improving operating trends and the company is generating positive free cash flow ($24.7M). At a market cap near $210M and an enterprise value of roughly $1.245B, the equity is deeply levered. If booking momentum continues and management keeps converting bookings into cash, …
Lockheed Martin's Q2 beat, a 3.2x book-to-bill in defense programs and heavy free cash flow have pushed the stock back into a valuation range that looks attractive for a tactical long. This trade idea lays out a clear entry at $580.00, a stop at $550.00 and an initial target of $640.00 over a mid-term (45 trading days) horizon — with an upside stre…
Genmab looks positioned to beat H1 revenue expectations on Darzalex strength and recent approvals momentum. The shares trade at $28.80 with a $17.9B market cap, reasonable 21.6x PE and improving technicals. We recommend a mid-term long trade into H1 results with a $29.00 entry, $34.00 target and $26.50 stop—duration ~45 trading days.
Amazon remains a core long-term growth story thanks to AWS and an aggressive $200B AI infrastructure push, but technicals, stretched near-term multiples vs. momentum, and macro rate risk justify a short-term downgrade to neutral. Trade plan: accumulate on a disciplined dip to $220 with a stop at $200 and a long-term target of $300 over the next 180…
MaxLinear has become a core AI-infrastructure play after a torrid run in 2026. Recent quarterly beats and aggressive guidance justify ownership, but stretched valuation and volatile technicals force a lower price target. I keep a Strong Buy with a mid-term trade plan: entry $65.00, target $95.00, stop loss $58.00, horizon ~45 trading days.
Digital Realty (DLR) is a dominant data-center REIT sitting at the intersection of constrained power supply and rising AI-driven capacity demand. Recent product launches and geographic expansion create a multi-quarter growth runway, but valuation and cash flow metrics require caution. This trade recommends a swing-long entry at $196, stop at $184, …
Immunovant (IMVT) looks like a compelling speculative buy here. The stock is trading just off its 52-week high with strong backing from a deep-pocketed strategic investor, a recently extended cash runway, and near-term clinical readouts that could re-rate the shares. Expect bumpy price action — size the position for high volatility and a binary cli…
Netflix is trading near 52-week lows despite strong margins, sizable free cash flow and a reasonable P/E. This trade lays out an actionable entry at $70.50, stop at $64.00 and a target of $94.50 with a mid-term horizon (45 trading days). The thesis: fundamentals and multiple tailwinds (ads, live sports, gaming) justify a recovery — but competition …
Highlander Silver (HSLV) emerged from a strategic combination and balance-sheet reset with roughly $100M in cash and no debt, three operating/near-operating precious-metal assets, and clear project milestones at Corani. This trade idea targets a material rerating if execution continues and financing needs remain limited; I lay out an entry at $4.45…
Heritage Insurance (HRTG) looks like a classic insurance recovery trade: cheap on earnings and free cash flow, high ROE, and positioned in Florida where El Nino should reduce Atlantic hurricane activity in 2026. I outline a long trade with entry at $28.54, a $40 target tied to a modest re-rating and continued underwriting discipline, and a $23.50 s…
Centuri ($27.33) is a utility infrastructure services company sitting on a record $5.9B backlog and accelerating revenue. With growing electric work, activist interest and a visible runway of funded utility projects, the stock looks like a compelling long-term trade to capture re-rating as revenue converts and margins expand. Entry $27.33, target $…
Carnival (CCL) has delivered record top-line momentum and improved cash flow, yet shares are pricing in demand uncertainty. A disciplined long swing captures upside if bookings and yields hold and geopolitical-driven fuel pressure stabilizes. Entry $27.12, target $34.00, stop $24.50 - mid-term trade (45 trading days) with clear risk management.
Taiwan Semiconductor (TSM) is the backbone of modern chip supply chains. Recent weakness has opened a clean, actionable long with a strong risk-reward: entry $399.27, stop $365.00, target $470.00 over a mid-term (45 trading days) horizon. The company’s scale, near-monopoly at leading process nodes, and a $100 billion U.S. investment make the valuat…
Revolution Medicines (RVMD) has rallied into a $40.7B market cap amid positive regulatory headlines for daraxonrasib and heavy institutional interest. The fundamentals - negative EPS (-$6.45), $1.07B trailing free cash flow burn and an enterprise value roughly equal to market cap - argue the rally is priced for near-perfect clinical and regulatory …
Verizon (VZ) offers a rare combination for income investors: a 6.3% yield, single-digit-to-low-teens P/E, and improving free cash flow backed by early AI-infrastructure revenue. With a market cap near $210.4B and signs of subscriber momentum in recent quarters, this is a trade for investors who prioritize yield and downside control. Entry $47.35, t…
